Crossject announced the signature of a commercial agreement on Midazolam with German Desitin.
19 Jun 2019
A commercial success
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A commercial success
Crossject SA (ALCJ:PAR) | 0 0 (-3.4%) | Mkt Cap: 38.7m
- Published:
19 Jun 2019 -
Author:
Fabrice Farigoule -
Pages:
2
Crossject announced the signature of a commercial agreement on Midazolam with German Desitin.